Home

Prothena Corporation plc - Ordinary Shares (PRTA)

14.23
-0.47 (-3.20%)

Prothena Corp is a biotechnology company focused on the discovery and development of innovative therapies to treat diseases caused by protein misfolding and aggregation

The company specializes in the research and development of monoclonal antibodies and other advanced treatments aimed at targeting neurodegenerative diseases, including Alzheimer's and Parkinson's. Through its proprietary platform, Prothena aims to address significant unmet medical needs by advancing its drug candidates through clinical trials, ultimately seeking to enhance the quality of life for patients suffering from these challenging conditions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · January 28, 2025
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga.com
Via Benzinga · December 20, 2024
Demystifying Prothena Corp: Insights From 6 Analyst Reviewsbenzinga.com
Via Benzinga · December 20, 2024
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Diseaseinvestors.com
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients.
Via Investor's Business Daily · December 19, 2024
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefitsbenzinga.com
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.
Via Benzinga · December 19, 2024
Expert Ratings For Prothena Corpbenzinga.com
Via Benzinga · November 13, 2024
Earnings Scheduled For November 12, 2024benzinga.com
Via Benzinga · November 12, 2024
Earnings Preview For Prothena Corpbenzinga.com
Via Benzinga · November 11, 2024
Breaking Down Prothena Corp: 4 Analysts Share Their Viewsbenzinga.com
Via Benzinga · October 1, 2024
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · December 19, 2024
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · October 28, 2024
Dow Dips 300 Points; Emcore Shares Spike Higherbenzinga.com
Via Benzinga · September 30, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · September 30, 2024
Demystifying Prothena Corp: Insights From 8 Analyst Reviewsbenzinga.com
Via Benzinga · March 13, 2024
Decoding 6 Analyst Evaluations For Prothena Corpbenzinga.com
Via Benzinga · February 16, 2024
Prothena Corp: Q4 Earnings Insightsbenzinga.com
Via Benzinga · February 15, 2024
Crude Oil Moves Higher; Prime Medicine Shares Spike Higherbenzinga.com
Via Benzinga · September 30, 2024
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024investorplace.com
PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Wininvestors.com
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
Via Investor's Business Daily · June 11, 2024
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024investorplace.com
PRTA stock results show that Prothena Corp missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setbackinvestors.com
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via Investor's Business Daily · March 28, 2024
Earnings Scheduled For February 15, 2024benzinga.com
Companies Reporting Before The Bell • Cognex (NASDAQCGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via Benzinga · February 15, 2024
Earnings Outlook For Prothena Corpbenzinga.com
Via Benzinga · February 14, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · February 29, 2024
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Shares of United Parcel Service, Inc. (NYSEUPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales
Via Benzinga · January 30, 2024